Kimberly Blackwell, M.D., has been leading Zentalis Pharmaceuticals, Inc. as the CEO since May 2022. She has a strong background in medicine, holding an M.D. from Mayo Clinic Medical School. Before taking the helm at Zentalis, she worked as the...

Kimberly Blackwell, M.D., has been leading Zentalis Pharmaceuticals, Inc. as the CEO since May 2022. She has a strong background in medicine, holding an M.D. from Mayo Clinic Medical School. Before taking the helm at Zentalis, she worked as the Chief Medical Officer at Tempus Labs, where she contributed to advancements in precision medicine through AI. Her previous roles include Vice President of Early-Stage Oncology at Eli Lilly, where she directed clinical teams on early-phase cancer treatments. At Duke University, she oversaw women's cancer research for nearly two decades, demonstrating her commitment to healthcare and education.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Zentalis Pharmaceuticals, Inc. CEOs

Z

Kimberly Blackwell, M.D.

Ex-CEO of Zentalis Pharmaceuticals, Inc.

Education

M.D. from Mayo Clinic Medical School

Field of Expertise

Healthcare & Life Sciences - Medicine

Sector of Economy

Healthcare

Born

January 1, 1969 - 56 years ago

CEO of Zentalis Pharmaceuticals, Inc. for

2 years 5 months (May 2022 - Nov 2024)

Previous Experience

Chief Medical Officer at Tempus Labs

Rivals

Competitors/colleagues of Kimberly Blackwell, M.D.

Holdings

See how much did Kimberly Blackwell, M.D. make over time.

As CEO of Zentalis Pharmaceuticals, Kimberly Blackwell holds a significant amount of ZNTL stock, reflecting her stake in the company's future. In mid-2023, she saw her holdings fluctuate wildly, peaking in February at approximately $12.44 million, which marked one of...

As CEO of Zentalis Pharmaceuticals, Kimberly Blackwell holds a significant amount of ZNTL stock, reflecting her stake in the company's future. In mid-2023, she saw her holdings fluctuate wildly, peaking in February at approximately $12.44 million, which marked one of her largest transactions. Following this peak, her interests decreased strategically, showing a value of $7.53 million in November 2023. It's clear that her financial commitment aligns with her vision for the company's growth, positioning her as not just a leader, but a key stakeholder in Zentalis' success.

Mar 18, 2025

Z

shares

ZNTL @ $1.77

Total Stock Sold

$313.63K

ZNTL

$313.63K

4,000 ZNTL shares

What if they kept their stock?

If Kimberly Blackwell, M.D. didn't sell their stock, today they would have:
Extra ZNTL4,000 shares worth $187.52K.
This is -40.21% and $126.11K less than what they got when they sold the stock.

Insider Trading

See recent insider trades of Kimberly Blackwell, M.D..

ZNTL

250,000 shares

ZNTL

Feb 1, 2024

Received

ZNTL

$51.45K

ZNTL at $10.29/share

Nov 13, 2023

Purchase

ZNTL

244,800 shares

ZNTL

Feb 1, 2023

Received

ZNTL

$83.74K

ZNTL at $83.74/share

Jan 3, 2022

Sale

ZNTL

$81.84K

ZNTL at $81.84/share

Dec 1, 2021

Sale

ZNTL

$80.46K

ZNTL at $80.46/share

Nov 1, 2021

Sale

ZNTL

$77.59K

ZNTL at $77.59/share

Oct 25, 2021

Sale

ZNTL

5,000 shares

ZNTL

Jun 4, 2021

Received

Compensation History

See how much did Kimberly Blackwell, M.D. make over time.

In 2023, Dr. Kimberly Blackwell earned $12,853,590 in total compensation as the CEO of Zentalis Pharmaceuticals. Her earnings package included a base salary of $701,425 and an annual cash bonus of $455,000, setting clear goals tied to corporate performance. Notably, she was granted stock options and RSUs valued at over $8 million, which ties her financial success directly to the company's performance. This shows a clear connection between her pay and the success of Zentalis, emphasizing the company's commitment to rewarding its leaders based on performance outcomes. Her previous year's compensation was significantly lower, which reflects her new role and responsibilities. This pay structure advocates for a results-driven culture within the company.

Year

2023

Total Compensation

$4.88M

Salary

$701.43K

Board Justification

The compensation program links executive pay to company performance, with a significant portion of compensation at risk based on achievement of corporate performance goals.

Bonus

$455.00K

Board Justification

Annual cash bonus based entirely on the achievement of corporate performance goals for 2023, paid out at 100% of target.

Other

$17.08K

Board Justification

Includes cellular phone plan allowance, group term life insurance premiums, and 401(k) matching contributions.

Restricted Stock

$3.71M(244.8K RSU)

Board Justification

RSUs vesting in four equal installments on each of the first four anniversaries of the grant date, subject to continued employment.

Performance Metrics

Corporate performance goals related to clinical development, future pipeline, financial objectives, and human capital management.

Other Zentalis Pharmaceuticals, Inc. CEOs

Here are other CEOs of Zentalis Pharmaceuticals, Inc.

Anthony Y. Sun, M.D.

Ex-CEO of Zentalis Pharmaceuticals, Inc.

January 2020 - May 2022

Julie Eastland

CEO of Zentalis Pharmaceuticals, Inc.

November 2024 - Present